Johnson & Johnson (JNJ) Operating Income (2009 - 2026)
Johnson & Johnson recorded quarterly Operating Income of $6.4 billion in Q1 2026, down 68.28% quarter-over-quarter from $20.1 billion in Q4 2025, and up 2.93% year-over-year from $6.2 billion in Q1 2025.
Johnson & Johnson's Operating Income history runs 18 years deep, the most recent figure standing at $6.4 billion for Q1 2026.
- In Q1 2026, Operating Income rose 2.93% year-over-year to $6.4 billion; the TTM figure through Mar 2026 stood at $40.1 billion (up 88.39% YoY), while the FY2025 annual figure was $39.9 billion, up 89.98% from the prior year.
- Operating Income came in at $6.4 billion for Q1 2026 at Johnson & Johnson, down from $20.1 billion in the prior quarter.
- In the past five years, Operating Income ranged from a high of $20.1 billion in Q4 2025 to a low of $3.6 billion in Q4 2024.
- A 5-year average of $7.4 billion and a median of $5.9 billion in 2024 frame the typical range for Operating Income.
- Across the five-year window, Operating Income plunged 80.91% in 2024 and jumped 457.46% in 2025, its largest moves.
- Johnson & Johnson's Operating Income stood at $5.3 billion in 2022, then surged by 255.78% to $18.9 billion in 2023, then slumped by 80.91% to $3.6 billion in 2024, then surged by 457.46% to $20.1 billion in 2025, then slumped by 68.28% to $6.4 billion in 2026.
- According to Business Quant data, Operating Income over the past three periods registered $6.4 billion, $20.1 billion, and $7.0 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 9.50 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 6.36 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 3.99 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | -7.73 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 2.67 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 2.59 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | -6.71 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | -182.00 Mn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 6.36 Bn |
| Dec 28, 2025 | 20.06 Bn |
| Sep 28, 2025 | 7.03 Bn |
| Jun 29, 2025 | 6.65 Bn |
| Mar 30, 2025 | 6.18 Bn |
| Dec 29, 2024 | 3.60 Bn |
| Sep 29, 2024 | 5.04 Bn |
| Jun 30, 2024 | 6.47 Bn |
| Mar 31, 2024 | 5.91 Bn |
| Dec 31, 2023 | 18.85 Bn |
| Oct 1, 2023 | 5.74 Bn |
| Jul 2, 2023 | 5.81 Bn |
| Apr 2, 2023 | 5.72 Bn |
| Jan 1, 2023 | 9.61 Bn |
| Oct 2, 2022 | 5.30 Bn |
| Jul 3, 2022 | 3.88 Bn |
| Apr 3, 2022 | 4.35 Bn |
| Oct 3, 2021 | 6.61 Bn |
| Jul 4, 2021 | 6.20 Bn |
| Apr 4, 2021 | 6.60 Bn |
| Jan 3, 2021 | 8.14 Bn |
| Sep 27, 2020 | 5.77 Bn |
| Jun 28, 2020 | 4.00 Bn |
| Mar 29, 2020 | 5.79 Bn |
| Dec 29, 2019 | 4.09 Bn |
| Sep 29, 2019 | 5.82 Bn |
| Jun 30, 2019 | 5.35 Bn |
| Mar 31, 2019 | 5.29 Bn |
| Dec 30, 2018 | 3.99 Bn |
| Sep 30, 2018 | 5.52 Bn |
| Jul 1, 2018 | 5.35 Bn |
| Apr 1, 2018 | 5.62 Bn |
| Dec 31, 2017 | 2.96 Bn |
| Oct 1, 2017 | 4.53 Bn |
| Jul 2, 2017 | 5.28 Bn |
| Apr 2, 2017 | 5.36 Bn |
| Jan 1, 2017 | 4.56 Bn |
| Oct 2, 2016 | 5.28 Bn |
| Jul 3, 2016 | 5.57 Bn |
| Apr 3, 2016 | 5.32 Bn |
| Jan 3, 2016 | 11.55 Bn |
| Sep 27, 2015 | 4.64 Bn |
| Jun 28, 2015 | 4.92 Bn |
| Mar 29, 2015 | 5.35 Bn |
| Dec 28, 2014 | 3.94 Bn |
| Sep 28, 2014 | 5.58 Bn |
| Jun 29, 2014 | 5.97 Bn |
| Mar 30, 2014 | 5.65 Bn |
| Dec 29, 2013 | 4.07 Bn |
| Sep 29, 2013 | 4.88 Bn |
| Jun 30, 2013 | 5.07 Bn |
| Mar 31, 2013 | 4.94 Bn |
| Dec 30, 2012 | 4.15 Bn |
| Sep 30, 2012 | 4.30 Bn |
| Jul 1, 2012 | 4.60 Bn |
| Apr 1, 2012 | 4.56 Bn |
| Jan 1, 2012 | 1.51 Bn |
| Oct 2, 2011 | 3.92 Bn |
| Jul 3, 2011 | 3.74 Bn |
| Apr 3, 2011 | 4.60 Bn |
| Jan 2, 2011 | 10.60 Bn |
| Oct 3, 2010 | 4.02 Bn |
| Jul 4, 2010 | 4.30 Bn |
| Apr 4, 2010 | 4.77 Bn |
| Jan 3, 2010 | 2.20 Bn |
| Sep 27, 2009 | 4.26 Bn |
| Jun 28, 2009 | 4.35 Bn |
| Mar 29, 2009 | 4.65 Bn |